CANY
VRTX icon

Caxton Associates (New York)’s Vertex Pharmaceuticals VRTX Stock Holding History

Caxton Associates (New York)’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,500
Closed -$1.64M – 659
2024
Q2 		$1.64M Sell
3,500
-2,269
-39% -$985K 0.06% 180
2024
Q1 		$2.41M Sell
5,769
-71,034
-92% -$30M 0.14% 105
2023
Q4 		$31.3M Buy
76,803
+71,624
+1,383% +$26.5M 1.6% 13
2023
Q3 		$1.8M Buy
5,179
+4,060
+363% +$1.42M 0.25% 69
2023
Q2 		$394K Buy
+1,119
New +$377K 0.06% 303
2023
Q1 		– Sell
-3,826
Closed -$1.1M – 648
2022
Q4 		$1.1M Sell
3,826
-1,232
-24% -$375K 0.07% 105
2022
Q3 		$1.46M Buy
5,058
+3,943
+354% +$1.13M 0.2% 53
2022
Q2 		$314K Buy
+1,115
New +$298K 0.03% 371
2022
Q1 		– Sell
-2,031
Closed -$446K – 724
2021
Q4 		$446K Sell
2,031
-2,396
-54% -$466K 0.05% 307
2021
Q3 		$803K Buy
+4,427
New +$864K 0.09% 127
2020
Q4 		– Sell
-2,961
Closed -$806K – 333
2020
Q3 		$806K Sell
2,961
-584
-16% -$161K 0.08% 67
2020
Q2 		$1.03M Buy
3,545
+2,375
+203% +$644K 0.09% 70
2020
Q1 		$278K Sell
1,170
-1,872
-62% -$429K 0.05% 275
2019
Q4 		$666K Buy
+3,042
New +$616K 0.09% 129
2017
Q4 		– Sell
-2,000
Closed -$304K – 539
2017
Q3 		$304K Buy
+2,000
New +$301K 0.01% 433

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Caxton Associates (New York)'s VRTX Position: Q3 2024 in Review

Caxton Associates (New York) sold out of Vertex Pharmaceuticals (VRTX) in Q3 2024, closing a stake of 3,500 shares — an estimated $1.64M sold.

Caxton Associates (New York) first reported a position in VRTX in Q3 2017 and held it in 15 quarters. The position peaked at $31.3M in Q4 2023. 1,544 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

  • Caxton Associates (New York) reported no remaining Vertex Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 3,500 Vertex Pharmaceuticals shares in Q3 2024, an estimated $1.64M.
  • Caxton Associates (New York) first reported a position in Vertex Pharmaceuticals in Q3 2017 and held it in 15 quarters.
  • Caxton Associates (New York)'s Vertex Pharmaceuticals position peaked at $31.3M in Q4 2023.
  • 1,544 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on Caxton Associates (New York)'s 13F filing for Q3 2024, filed 14 Nov 2024.